Valuation: NeoStem Inc

Market Cap 13.43M 11.93M 11.15M 10.16M 19.13M 1.29B 19.4M 135M 52.23M 658M 50.41M 49.32M 2.11B P/E 2026 *
-1.37x
P/E 2027 * -1.28x
Enterprise Value 13.43M 11.93M 11.15M 10.16M 19.13M 1.29B 19.4M 135M 52.23M 658M 50.41M 49.32M 2.11B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
77.73%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 69 04/01/2015
Director of Finance/CFO 55 31/07/2020
President 52 16/09/2026
Director TitleAgeSince
Director/Board Member 69 04/01/2015
Chairman 72 15/02/2017
Director/Board Member 66 31/10/2018
Change 5-day change 1-year change 3-year change Capi.($)
+4.16%+3.04%+49.37%+94.17% 74.41B
-3.16%-3.34%+22.16%+74.95% 59.26B
+1.32%-0.21%+4.72%+35.08% 47.14B
+0.39%-5.20%+27.94%+32.51% 42.91B
+0.29%+3.02%+348.95%+643.82% 44.13B
-2.09%-0.33%+7.04%+99.46% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-2.68%+2.92%+29.63%+22.72% 29.31B
-1.79%-10.66%-26.27%+330.06% 23.71B
Average +0.06%-0.52%+52.63%+153.78% 43.6B
Weighted average by Cap. +0.36%-0.32%+57.72%+145.34%

Financials

2026 *2027 *
Net sales - -
Net income -18.3M -16.25M -15.2M -13.85M -26.08M -1.76B -26.44M -184M -71.19M -897M -68.71M -67.22M -2.88B -21.1M -18.74M -17.53M -15.97M -30.07M -2.03B -30.48M -212M -82.08M -1.03B -79.22M -77.5M -3.32B
Net Debt - -
Logo NeoStem Inc
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.
Employees
-